H. Lundbeck A/S

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-12-11 am EST			5-day change	1st Jan Change
43.44 ^DKK	-1.27%		-1.32%	+5.13%

Dec. 08	Lundbeck Reports Long-Term Positive Phase 2 Data for Bexicaserin in Rare Pediatric Epilepsies	FW
Dec. 03	BNP Paribas Exane Raises Price Target for Lundbeck to 45 Danish Kroner, Reiterates Neutral Rating - BN	FW

Swixx BioPharma and H. Lundbeck A/S Sign Multi-Regional CNS Partnership

Published on 09/10/2025 at 02:35 am EDT

S&P Capital IQ

H. Lundbeck A/S

-1.27%

HBM Healthcare Investments AG

+1.43%

US Dollar / Turkish Lira (USD/TRY)

-0.05%

HBM Healthcare Investments announced that its portfolio company Swixx BioPharma, and its affiliated companies (Swixx) have signed a transformative, multi-regional distribution and services agreement with H. Lundbeck A/S. Under the agreement, Swixx will distribute and commercialise Lundbeck's entire in-market central nervous system (CNS) portfolio across selected markets in three key regions: South-East Europe (including Israel and Russia), Turkey and Latin America. This multi-regional partnership includes novel and mature therapies for psychiatric and neurological conditions and further establishes Swixx as a major player in the CNS therapeutic area. It also highlights the growing industry trend of outsourcing commercial operations in emerging markets.

The partnership exemplifies Swixx's ability to deliver value through local expertise, operational excellence and strategic vision -- an approach that aligns with HBM Healthcare Investments' commitment to supporting outstanding entrepreneurs and innovative ventures.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
H. LUNDBECK A/S	43.44DKK	-1.27%	-1.32%	6.52B
HBM HEALTHCARE INVESTMENTS AG	212.50CHF	+1.43%	+3.41%	1.74B
US DOLLAR / TURKISH LIRA	42.5770TRY	-0.05%	+0.18%	-

Latest news about H. Lundbeck A/S

Dec. 08	Lundbeck Reports Long-Term Positive Phase 2 Data for Bexicaserin in Rare Pediatric Epilepsies	FW
Dec. 03	BNP Paribas Exane Raises Price Target for Lundbeck to 45 Danish Kroner, Reiterates Neutral Rating - BN	FW
Dec. 02	H. Lundbeck A/S Presents Comprehensive New Bexicaserin Dataset Epilepsies	CI
Dec. 02	Lundbeck Presents Promising Data for New Epilepsy Drug	FW
Nov. 26	Lundbeck Will Not Raise Its Bid for Avadel	FW
Nov. 20	UBS Raises Lundbeck Target Price to 46 Danish Kroner, Maintains Neutral Rating	FW
Nov. 19	Alkermes Raises Offer for Avadel to $22.50 Per Share	FW
Nov. 18	Barclays Raises Price Target for Lundbeck to 53 Danish Kroner, Reiterates Equal Weight	FW
Nov. 17	Avadel Pharmaceuticals Board Deems Lundbeck's Takeover Proposal Superior	FW
Nov. 14	H Lundbeck lifts guidance again as migraine and depression drugs drive growth
Nov. 13	H. Lundbeck A/S (CPSE:HLUN B) submitted a non binding proposal to acquire Avadel Pharmaceuticals plc for $2.1 billion.	CI
Nov. 14	Lundbeck Makes Bid for Irish Firm Avadel Pharmaceuticals	FW
Nov. 14	Lundbeck's New Drug Application for Migraine Preventive Drug Accepted by Japanese Ministry	MT
Nov. 14	Lundbeck Seeks Market Approval for Vyepti in Asia	FW
Nov. 14	H. Lundbeck A/S Announces the Acceptance of Its New Drug Application	CI
Nov. 13	Kepler Cheuvreux Raises Target Price for Lundbeck to 65 Danish Kroner, Reiterates Buy	FW
Nov. 13	SEB Raises Price Target for Lundbeck to 50 Danish Kroner, Reiterates Hold	FW
Nov. 12	H. Lundbeck A/S, Q3 2025 Earnings Call, Nov 12, 2025
Nov. 12	Nordea Raises Target Price for Lundbeck to 72 Danish Kroner (71), Reiterates Buy	FW
Nov. 11	H. Lundbeck A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 11	H. Lundbeck A/S Increases Revenue Guidance for Full Year of 2025	CI
Nov. 11	H. Lundbeck Upgrades FY25 Revenue Outlook	MT
Nov. 11	Lundbeck Surpasses Expectations with Strong Q3 2025 Results	FW
Nov. 11	Lundbeck Raises 2025 Forecast Following Strong Demand	FW
Nov. 11	Jefferies Downgrades Lundbeck on Patent Concerns	FW

Chart H. Lundbeck A/S

Duration

Period

HLUN B: Dynamic Chart

Company Profile

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâs disease, Bipolar disorder, depression, epilepsy, Huntingtonâs disease, Parkinsonâs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâs disease, Azilect for the treatment of Parkinsonâs disease, Xenazine for the treatment of Huntingtonâs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Employees

5,700

Sector

Pharmaceuticals

Calendar

Feb. 10 - Q4 2025 Earnings Release (Projected)

More about the company